EA201100391A1 - Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы - Google Patents

Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы

Info

Publication number
EA201100391A1
EA201100391A1 EA201100391A EA201100391A EA201100391A1 EA 201100391 A1 EA201100391 A1 EA 201100391A1 EA 201100391 A EA201100391 A EA 201100391A EA 201100391 A EA201100391 A EA 201100391A EA 201100391 A1 EA201100391 A1 EA 201100391A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
aminoxidase
semicarbazid
sensitive
activity inhibiting
Prior art date
Application number
EA201100391A
Other languages
English (en)
Other versions
EA019167B1 (ru
Inventor
Эдвард Сэйвори
Майкл Хиггинботтом
Энн Вьет-Ан Хорган
Кэтрин Оливер
Original Assignee
Проксимаген Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проксимаген Лимитед filed Critical Проксимаген Лимитед
Publication of EA201100391A1 publication Critical patent/EA201100391A1/ru
Publication of EA019167B1 publication Critical patent/EA019167B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к соединениям формулы (I)а также их фармацевтически приемлемым солям, сольватам, гидратам, геометрическим изомерам, таутомерам, оптическим изомерам или N-оксидам, являющимся ингибиторами активности SSAO. Изобретение также относится к фармацевтическим композициям, содержащим данные соединения, а также к способам применения данных соединений при лечении и профилактике медицинских показаний, при которых ингибирование активности SSAO имеет благоприятный эффект, аналогичных воспалительным заболеваниям и иммунологическим нарушениям.
EA201100391A 2008-09-16 2009-09-16 Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы EA019167B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0801979 2008-09-16
US10673408P 2008-10-20 2008-10-20
PCT/EP2009/062011 WO2010031789A1 (en) 2008-09-16 2009-09-16 New compounds i

Publications (2)

Publication Number Publication Date
EA201100391A1 true EA201100391A1 (ru) 2011-10-31
EA019167B1 EA019167B1 (ru) 2014-01-30

Family

ID=41226693

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100391A EA019167B1 (ru) 2008-09-16 2009-09-16 Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы

Country Status (16)

Country Link
US (7) US8263616B2 (ru)
EP (1) EP2334672B1 (ru)
JP (1) JP5539989B2 (ru)
CN (1) CN102232073B (ru)
AU (1) AU2009294660B2 (ru)
BR (1) BRPI0918602B8 (ru)
CA (1) CA2737527C (ru)
DK (1) DK2334672T3 (ru)
EA (1) EA019167B1 (ru)
ES (1) ES2440279T3 (ru)
HK (1) HK1159102A1 (ru)
MX (1) MX2011002581A (ru)
NZ (1) NZ592238A (ru)
PL (1) PL2334672T3 (ru)
PT (1) PT2334672E (ru)
WO (1) WO2010031789A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440279T3 (es) 2008-09-16 2014-01-28 Proximagen Limited Compuestos de 4,5,6,7-tetrahidroimidazo[4,5-c]piridina como inhibidores de SSAO
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
CN102311396B (zh) * 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
CA2847193A1 (en) 2011-09-14 2013-03-21 Proximagen Limited New enzyme inhibitor compounds
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
AU2014279863A1 (en) 2013-06-12 2016-01-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
US10631037B2 (en) 2015-03-02 2020-04-21 Nec Corporation Decoding device, reception device, transmission device, transmission/reception system, decoding method, and storage medium having decoding program stored therein
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201507036D0 (en) 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
GB201513115D0 (en) * 2015-07-24 2015-09-09 Proximagen Ltd New therapeutic compound and use in therapy
AU2016366635A1 (en) * 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
GB201618029D0 (en) * 2016-10-25 2016-12-07 Proximagen Ltd New process
WO2020139988A1 (en) * 2018-12-28 2020-07-02 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5285191A (en) * 1976-01-07 1977-07-15 Farmaceutici Italia Novel 4*5*6*77tetrahydroimidazoo *4*55c*pyridine derivative process for preparing same and medicine having antiiulcer antiisecretion and antiicolline activities containing same
US4141899A (en) * 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) * 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
SE0004101D0 (sv) * 2000-11-09 2000-11-09 Pharmacia Ab New use
US6576249B1 (en) * 2000-11-13 2003-06-10 El Gendler Bone putty and method
ES2440279T3 (es) 2008-09-16 2014-01-28 Proximagen Limited Compuestos de 4,5,6,7-tetrahidroimidazo[4,5-c]piridina como inhibidores de SSAO

Also Published As

Publication number Publication date
US8569338B2 (en) 2013-10-29
CN102232073A (zh) 2011-11-02
JP2012506368A (ja) 2012-03-15
ES2440279T3 (es) 2014-01-28
US9035066B2 (en) 2015-05-19
US9493457B2 (en) 2016-11-15
US8263616B2 (en) 2012-09-11
BRPI0918602B1 (pt) 2020-04-07
US20110207746A1 (en) 2011-08-25
NZ592238A (en) 2012-11-30
CN102232073B (zh) 2014-10-29
AU2009294660B2 (en) 2013-11-14
US20150218161A1 (en) 2015-08-06
US9890160B2 (en) 2018-02-13
PL2334672T3 (pl) 2014-03-31
JP5539989B2 (ja) 2014-07-02
US20170044157A1 (en) 2017-02-16
PT2334672E (pt) 2014-01-02
EP2334672B1 (en) 2013-11-20
WO2010031789A1 (en) 2010-03-25
HK1159102A1 (en) 2012-07-27
US20180118744A1 (en) 2018-05-03
CA2737527C (en) 2015-12-29
US20120302583A1 (en) 2012-11-29
US20190359611A1 (en) 2019-11-28
BRPI0918602A2 (pt) 2015-12-15
AU2009294660A1 (en) 2010-03-25
US11040969B2 (en) 2021-06-22
EA019167B1 (ru) 2014-01-30
MX2011002581A (es) 2011-04-07
DK2334672T3 (da) 2013-12-02
CA2737527A1 (en) 2010-03-25
EP2334672A1 (en) 2011-06-22
US20140121219A1 (en) 2014-05-01
US10399973B2 (en) 2019-09-03
BRPI0918602B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201170922A1 (ru) Производные сульфонамида
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
ATE517882T1 (de) Chinolinderivate
UA111770C2 (uk) Інгібітори бромдомену
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
MA33304B1 (fr) Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent